HispanicBusiness

OTTAWA, ONTARIO -- (Marketwire) -- 03/01/13 -- Canada's Research-Based Pharmaceutical Companies (Rx&D) is pleased to announce that Novo Nordisk Canada Inc. has joined the association, which represents the innovative pharmaceutical industry in Canada.

"More and more companies are recognizing the value of Rx&D membership, which includes our Code of Ethical Practices and our patient-focused, collaborative approach to developing sustainable healthcare solutions for Canada. We are pleased to welcome Novo Nordisk and their expertise which gives us a broader foundation, making the research-based pharmaceutical industry even stronger," said Rx&D President Russell Williams.

"At Novo Nordisk, we are committed to helping Canadians achieve the best health outcomes. Ninety years ago our Danish founders began a journey to change diabetes. Today, our passion is providing innovations to patients around the world"," said Vince Lamanna, President, Novo Nordisk Canada. "We look forward to working with Rx&D in the months and years ahead to ensure our industry is able to bring the best possible care to Canadians.

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

About Novo Nordisk Canada Inc.

Novo Nordisk is a healthcare company and a world leader in diabetes care and biopharmaceuticals. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. For more information, visit www.novonordisk.ca.



Add to Digg Bookmark with del.icio.us Add to Newsvine



Contacts:
Isabelle Robillard
Director, Media Relations
613-236-0455 extension 831
irobillard@canadapharma.org